author-photo

Jennifer Cultrera

Sarah Cannon Research Institute

4

Papers

27

Citations

Citation Trend

Filter By

Papers (4) Sort By

Journal Conference Others

Ramucirumab in Combination with Pembrolizumab in Treatment-Naïve Advanced Gastric or GEJ Adenocarcinoma: Safety and Antitumor Activity from the Phase 1a/b JVDF Trial.

2020 Cancers
Show All
- Source
- Cite
- Save
Citations (2)
Umbralisib Plus Ublituximab (U2) Is Superior to Obinutuzumab Plus Chlorambucil (O+Chl) in Patients with Treatment Naïve (TN) and Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia (CLL): Results from the Phase 3 Unity-CLL Study

2020 Blood
Show All
- Source
- Cite
- Save
Citations (17)
SO-002Safety and antitumor activity from the phase Ib study of ramucirumab plus pembrolizumab in treatment-naïve advanced gastric or gastroesophageal junction (G/GEJ) adenocarcinoma (JVDF)

2019 Annals of Oncology
Show All
- Source
- Cite
- Save
Citations (2)
Phase 1b/2 study of enzalutamide (ENZ) with LY3023414 (LY) or placebo (PL) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) after progression on abiraterone.

2019 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (6)